Stay updated with breaking news from Jacques Bouchy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SEATTLE, Dec. 12, 2023 -- Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced...
SEATTLE, Oct. 09, 2023 -- Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced...
SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...
11.08.2023 - Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into ...
Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 ... | May 11, 2023